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Abstract
Background: Azole-based antifungals are the first-line therapy for some of the most common mycoses and are now
also being used prophylactically to protect immunocompromised patients. However, due to variability in both their
metabolism and bioavailability, therapeutic drug monitoring is essential to avoid toxicity but still gain maximum efficacy.
Methods: Following protein precipitation of serum with acetonitrile, 20L of extract was injected onto a 2.1 50mm
Waters Atlantis dC18 3m column. Detection was via a Waters Quattro Premier XE tandem mass spectrometer
operating in ESI-positive mode. Multiple reaction monitoring (MRM) detected two product ions for each compound and
one for each isotopically labelled internal standard. Ion suppression, linearity, stability, matrix effects, recovery, impre-
cision, lower limits of measuring interval and detection were all assessed.
Results: Optimal chromatographic separation was achieved using gradient elution over 8 minutes. Voriconazole, posa-
conazole and itraconazole eluted at 1.71, 2.73 and 3.41min, respectively. The lower limits of measuring interval for all
three compounds was 0.1mg/L. The assay was linear to 10mg/L for voriconazole (R2¼ 0.995) and 5mg/L for posacon-
azole (R2¼ 0.990) and itraconazole (R2¼ 0.991). The assay was both highly accurate and precise with % bias of vor-
iconazole, posaconazole and itraconazole, respectively, when compared with previous NEQAS samples. The intra-assay
precision (CV%) was 1.6%, 2.5% and 1.9% for voriconazole, posaconazole and itraconazole, respectively, across the linear
range.
Conclusion: A simple and robust method has been validated for azole antifungal therapeutic drug monitoring. This new
assay will result in a greatly improved sample turnaround time and will therefore vastly increase the clinical utility of azole
antifungal drug monitoring.
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Introduction
Voriconazole, posaconazole and itraconazole are the
three most commonly prescribed members of the
azole antifungal family, which in turn makes up one
of the four classes of antifungal medications, along
with polyenes, allylamines and echinocandins. The
family is named after, and deﬁned, by their chemical
structure, and therefore each member contains at least
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one tri-nitrogen containing ﬁve-membered heterocyclic
moiety (Table 1). The azoles target fungal membrane
formation and inhibit lanosterol 14 a-demethylase, a
key enzyme required for ergosterol production.1
Ergosterol is an essential component of fungi cell mem-
branes performing a similar function to cholesterol in
mammalian cell membranes.
The use of these newer antifungals is increasing as a
direct result of the rise in invasive fungal infections
(IFIs).2,3 IFIs are the collective name given to any
deep tissue mycoses, which can be fatal unless eﬀectively
treated. The increased danger of IFIs is associated with
the prerequisite that only immunocompromised patients
are susceptible to these infections. Therefore, the devel-
opment of a deep tissue fungal infection in patients cur-
rently receiving chemotherapy, on immunosuppressive
therapies or with other co-morbidities requires prompt,
eﬀective treatment to avoid mortality.
From the chemical structures alone, it is apparent
that posaconazole and itraconazole will be hydrophobic,
which is conﬁrmed by their highly protein bound nature
(in the aqueous serum environment) and their high par-
tition coeﬃcients (log P values) (Table 1). The variation
in hydrophobicity between the three antifungals is
known to confer diﬀerences in bioavailability and
would also be expected to be problematic during chro-
matography development. Unfortunately, all three of
these antifungal drugs have a non-linear relationship
between dose and eﬃcacy; therefore, therapeutic drug
monitoring (TDM) is essential.4 Indeed, recent meta-
analysis has shown that the correct, therapeutic dose
of voriconazole doubles the patient’s chances of a posi-
tive outcome.5 Voriconazole exhibits non-linear
metabolism/excretion due to variability in P450 enzymes
(CYP2C19, CYP3A4 and CYP2C9) which can be either
up- or down-regulated by other common drugs.6,7
Posaconazole has conﬁrmed linear kinetics, but absorp-
tion becomes saturated with doses above 800mg/day.8
Itraconazole has variable bioavailability and non-linear
metabolism which has been shown to arise from satur-
ation of the hydroxylase involved in the ﬁrst step of
metabolism.9 The case for TDM for all three of these
drugs has been coherently made and is now recom-
mended in treatment guidelines.10–12 However, the ana-
lysis of samples for azole TDM is still only performed in
specialist regional centres resulting in delayed turn-
around times. The reporting of results ﬁve to seven
days after the sample is taken reduces the clinical utility
of the test and has resulted in poor testing compliance
from clinicians.
Although several clinical laboratories in the
United Kingdom currently perform antifungal TDM
using liquid chromatography tandem mass spectro-
metry (LC-MS/MS), to date none have published
their method. Worldwide the few methods that have
been published fail to address the needs of routine
clinical laboratories by either publishing overly com-
plex assays which included drugs that are not rou-
tinely monitored or have failed to validate their
methods in line with the current clinical guidance.13,14
The assay presented herein oﬀers a simple, quick
and accurate method for azole TDM that has been
speciﬁcally designed to be introduced alongside exist-
ing LC-MS/MS methods making azole antifungal
TDM a realistic prospect for nearly all clinical
laboratories.
Table 1. Chemical structures and selected pharmacokinetic parameters for voriconazole, posaconazole and itraconazole.
Name (Brand Name) Chemical Structure
% Protein
Bound Vd (L/kg)
LogP
(octanol:water)
Voriconazole (Vfend) 58 4.6 1.82
Posaconazole (Noxafil) >98 7–25 5.41
Itraconazole (Sporanox) 99.8 11 7.31
Vd: volume of distribution.
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Materials and methods
Materials
Voriconazole, posaconazole and itraconazole were pur-
chased individually as Cerilliant standards (Sigma-
Aldrich, Dorset, UK) at a concentration of 2mg/mL
in methanol. D3-voriconazole, D4-posaconazole
and D3-itraconazole (Toronto Research Chemicals,
Canada) were used as internal standards; these com-
pounds arrived lyophilized and were re-dissolved in
methanol to a concentration of 2mg/mL. Then 1%
hydrochloric acid (1M) was added to the D3-itracona-
zole solution to aid solubility. Following initial develop-
ment work using methanolic calibrators,
commercial lyophilized whole blood quality control
(QC) material and calibrators were purchased from
both Recipe (RECIPE Chemicals and Instruments
GmbH, Germany) and Chromsystems (Chromsystems
Instruments & Chemicals GmbH, Germany). The inter-
nal standards were diluted in 50:50 methanol:water and
used to prepare a combined working internal standard
solution of; D3-voriconazole (1mg/L), D4-posacona-
zole (1mg/L) and D3-Itraconazole (5mg/L). Both the
Cerilliant standards and deuterated internal standards
were stored at 20C until required. All methanol and
acetonitrile were LC-MS/MS grade purchased from
Sigma (Sigma-Aldrich, Dorset, UK). Hydrochloric
acid (ACS reagent grade, 1M) and ammonium acetate
(BioXtra, 598%) were purchased from Sigma (Sigma-
Aldrich, Dorset, UK). Formic acid (Biosolve,
99% ULC-MS) was purchased from Greyhound
Chromatography (Greyhound Chromatography and
Allied Chemicals, Birkenhead, UK). The water used
for both dilutions and mobile phases was produced in-
house using a MilliQ (Millipore, Darmstadt, Germany)
puriﬁcation system to a resistivity of518.2M cm.
Sample preparation
Patient serum, QCs or calibrators (100mL) were com-
bined with working internal standard solution (100mL)
in a microcentrifuge tube. Acetonitrile (200 mL) was
then added to precipitate the serum proteins. The sus-
pension was then mixed for 15 s using a vortex mixer
and centrifuged at room temperature (5min,
10,000 g).The sample was then sealed and stored at
4C, until it was injected onto the column.
Chromatography
Liquid chromatography was performed on a Waters
Alliance 2795 separation module. Extracted sample
(25L) was injected onto a Waters Atlantis column
3m dC18 (2.1 50mm) column (Waters,
Hertfordshire, UK). The column was maintained at
30C throughout the assay. Mobile phase A contained
ammonium acetate (2mM) and formic acid (0.1 % v/v)
in water. Mobile phase B had the same composition but
dissolved in methanol. Initial conditions were 45%
mobile phase B. Following sample injection, elution
was performed by means of a multistep gradient at a
constant ﬂow rate of 0.6mL/min starting from 45% to
75% mobile phase B over 1min, before being held at
75% mobile phase B for a further 1min. Following this,
the proportion of mobile phase B was increased to 98%
over 2min and held at 98% mobile phase B for a fur-
ther 3.5min. Finally, the mobile phase was returned to
starting conditions (45%) for the remaining 0.5min
before the next injection. An automated programme
of three consecutive strong washes consisting of 100%
methanol was used to clean the sample injector between
sample injections.
Mass spectrometry
Tandem mass spectrometry analysis was performed on
a Waters Quattro Premier XE system (Waters,
Manchester, UK) interfaced with a Z-spray electro-
spray ionization (ESI) source. The ESI source was
operated in the positive electrospray ionization mode
at a capillary voltage of 3.0 kV, extractor cone voltage
of 50V, RF lens voltage of 0.3V, source temperature of
120C, desolvation temperature of 200C and desolva-
tion gas ﬂow of 900L/h. The individual transitions,
cone voltages and collision energies for each of the
analytes and internal standards are shown in Table 2.
MassLynx software (Version 4.1; Waters,
Manchester, UK) was used for instrument control,
data acquisition, peak smoothing, peak area integra-
tion and signal-to-noise determinations. Statistical ana-
lysis was performed using a combination of Microsoft
Excel (2016) and GraphPad Prism 6.
Method validation
The LC-MS/MS method was validated for precision,
accuracy, recovery, linearity, sensitivity, speciﬁcity
Table 2. Mass spectrometer detector settings for quantifier,
qualifier and internal standard MRM transitions.
Precursor
ion (m/z)
Product ions (m/z) Cone
voltage
(V)
Collision
energy
(eV)Quantifier Qualifier
Voriconazole 350.3 127.2 281.0 25 25
D3 Voriconazole 353.3 284.1 25 25
Posaconazole 701.5 683.2 614.2 40 40
D4 Posaconazole 705.6 127.0 40 40
Itraconazole 705.3 392.2 173.8 50 40
D3 Itraconazole 708.5 255.9 50 40
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and sample stability according to published acceptance
criteria.13,14
Ion suppression
Ion suppression was evaluated through both post-
column infusion and matrix factor experiments. Each
analyte (1mg/L) in 50:50 methanol:water was infused
directly into the mass spectrometer at a ﬂow rate of
10L/min, while the extracted samples of either water
or antifungal free patient serum were introduced separ-
ately via the auto sampler, through the column. Ion
suppression/enhancement was interpreted by any fall
or rise in the total baseline ion count around the reten-
tion time of the analyte.
The eﬀect the matrix has upon the ionization and
detection of ions was also investigated using matrix
factor experiments. These experiments were performed
in two potential matrices, water and serum. The serum
of six patients (who were not currently taking any anti-
fungal drugs) and ﬁltered water was spiked with water,
to create a blank, individually with each internal stand-
ard and with each analyte to a ﬁnal concentration of
1mg/L. The matrix factor was determined by compari-
son of peak areas achieved from analyses of the serum
samples, to the areas achieved from the analysis of the
water samples.
Linearity
Linearity was determined separately for each analyte by
analysis of multiple calibrators. For voriconazole, eight
calibrators with concentrations 0.1, 0.5, 1, 2, 4, 6, 8 and
10mg/L were analysed, while for posaconazole and
itraconazole seven calibrators with concentrations 0.1,
0.5, 1, 2, 3, 4 and 5mg/L were used. QuanLynx soft-
ware (Version 4.1; Waters, Manchester, UK) was used
to plot nominal values against the generated LC-MS/
MS peak areas. Linearity of the calibrators was con-
ﬁrmed if the correlation coeﬃcient produced by
weighted linear regression was >0.99.
Carryover
Carryover was assessed individually for each analyte by
repeat (n¼ 5) analysis of the highest calibrator followed
by analysis of a blank. Blank samples were deﬁned as
having no discernible peak for the analyte or internal
standard at the expected retention time.
Stability
Post-extraction stability of each analyte in both patient
(n¼ 9) and QC samples (n¼ 9) was assessed by repeat
injections of samples over a seven-day period, after
storage at either 4C or room temperature. The
response of each analyte was then compared with the
response on day 0 and the mean percentage diﬀerence
calculated.
Recovery
Recovery experiments were performed individually for
each of the three analytes. Serum from ﬁve patients was
spiked pre-extraction with 10L of analyte at three dif-
ferent concentrations (0.1, 1 and 10mg/L) or 100L of
internal standard. The calculated concentrations from
the samples spiked pre-extraction were then compared
with the known concentration used to spike the sample.
Imprecision
Intra-assay precision was evaluated by the analysis of
ﬁve sets of QC in one batch. The commercial QC sam-
ples were analysed as unknowns and compared by the
comparison of peak areas.
Inter-assay precision was evaluated by the analysis
of ﬁve sets of QC on ﬁve diﬀerent batches prepared and
analysed on ﬁve separate, non-consecutive days.
Lower limit of measuring interval
Lower limit of measuring interval (LLMI) was deter-
mined individually for each analyte by assessment of
the signal-to-noise ratio and comparison of percentage
diﬀerence. LLMI was assigned to the minimum clinic-
ally relevant concentration that had a percentage dif-
ference <20% and a signal-to-noise ratio >5:1. The
percentage diﬀerence was calculated by comparison of
the experimentally derived concentrations from ﬁve
replicates to the predicted concentration.
Accuracy
The accuracy of the assay was evaluated by the meas-
urement of external quality assurance (EQA) samples,
n¼ 25 for each analyte. The results were then compared
against the all-laboratory trimmed mean as individual
method means were unavailable.
Results
Voriconazole, posaconazole and itraconazole had
retention times of 1.71, 2.73 and 3.41min, respectively.
All three compounds co-eluted with their deuterated
equivalents (Figure 1). The total chromatographic run
time was 8min, a solvent divert was set up between 0–1
and 5–8min.
Qualitative ion suppression proﬁles demonstrated no
signiﬁcant suppression or enhancement of signal in the
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Figure 1. (a) voriconazole (1mg/L), (b) posaconazole (1mg/L), (c): itraconazole (1mg/L). Red trace – multiple reaction monitoring
trace for each analyte. Green trace – multiple reaction monitoring trace for each deuterated internal standard (D3–voriconazole
(1mg/L), D4–posaconazole (1mg/L) and D3-itraconazole (5mg/L)).
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region of the chromatograms where voriconazole,
posaconazole or itraconazole eluted (Figure 2).
Additionally, quantitative ion suppression experiments,
assessed by comparison of the peak areas generated
from known concentration of analyte spiked into
both serum samples and water yielded matrix factors
of 1.01 (CV 11.8%), 1.12 (CV 16.1%) and 1.09 (CV
12.8%) for voriconazole, posaconazole and itracon-
azole, respectively. Similar experiments but spiking
internal standard produced matrix factors of 1.22 (CV
10.6%), 1.02 (CV 6.9%) and 0.94 (CV 11.7%) for D3-
voriconazole, D4-posaconazole and D3-itraconazole,
respectively.
The assay was linear up to 10mg/L for voriconazole.
The linearity of itraconazole and posaconazole was
only evaluated up to 5mg/L. The linearity was assessed
by linear regression analysis consistently giving R2
values >0.99. The LLMI was deﬁned as 0.1mg/L for
all three analytes, as this was deemed the minimum
clinically relevant concentration. At this concentration,
the percentage diﬀerence of the experimental result
compared with the predicted result for each analyte
was less than <10% and the signal-to-noise ratio was
>10:1. Carryover between the lowest and highest cali-
brators was evaluated by interspacing high calibrators
with blanks and comparing the blank area to the LLMI
peak area. Each of the three analytes showed no carry-
over with the blank area consistently less that 5% of
the LLMI.
No systematic loss in sensitivity was observed over
seven days for any of the three analytes, irrespective of
whether the samples were stored at 4C or room tem-
perature. The variation of repeat analysis compared
with the initial concentrations was within 15% of all
analytes for both sets of samples. The mean recovery
eﬃciency (n¼ 15) for voriconazole, posaconazole and
itraconazole was 103% (range: 98–110), 95% (range:
90–100) and 103% (range: 98–110), respectively.
Intra- and inter-assay imprecision in all quality control
materials tested yielded CV values <11% (Table 3).
Due to the diﬃculty obtaining suﬃcient samples to
facilitate a sample swap, accuracy was determined by
the analysis of previous EQA samples (n¼ 25 for each
analyte). The experimentally determined concentra-
tions were compared with the published all laboratory
trimmed mean (Figure 3). Mean bias from the all
laboratory trim mean (ALTM) target values was
4.7%, 0.5% and 1.1% for voriconazole, posaconazole
and itraconazole, respectively.
Discussion
This method was developed in response to clinical need
and was therefore designed to have maximum clinical
utility. From its inception, it was decided to develop a
combined assay for voriconazole, posaconazole and
itraconazole as these three drugs make-up the ﬁrst-
line treatments for the most common fungal infections.
The inclusion of other azole-based drugs was con-
sidered, but many of those have been largely super-
seded by second-generation azole drugs such as
voriconazole, posaconazole and itraconazole and there-
fore their use is in decline. Special consideration was
given to the inclusion of ﬂuconazole in this assay.
However, due to its reduced potency in comparison
to itraconazole and its eﬃcacy being limited to yeasts,
its popularity was deemed insuﬃcient to warrant
inclusion.
The sample preparation was deliberately kept as
quick and simple as possible. The current relatively
low, but increasing, numbers of azole TDM performed
within the Trust necessitated that this new method
would need to be quick, simple to perform and utilize
only pre-existing equipment for this assay to become
viable. Therefore, with these pre-requisites, zinc sul-
phate was initially trialled as the protein precipitating
agent and was added to the patient samples in a 2:1 v/v.
However, these early experiments showed zinc sulphate
completely precipitated itraconazole and its internal
standard from samples. The reason for this must
derive from the chemical structure of itraconazole and
its lipophilicity. The log P of itraconazole is higher than
the other two compounds in this assay and even exceeds
the suggested lipophilicity of drug molecules. Lipinski’s
rule for predicting poor absorption and permeability
suggest drugs should have a log P of <5.15 As itracon-
azole is highly insoluble in water, the addition of an
aqueous protein-precipitating agent needed to be
avoided. In a deliberate attempt to avoid the additional
steps generated by an extraction-based puriﬁcation,
protein precipitation with acetonitrile was attempted.
Addition of two equivalents of acetonitrile proved
very eﬀective, producing a clear extract and allowed
excellent chromatographic separation of all three ana-
lytes. The extraction eﬃciency was evaluated (data not
shown) and shown to be 50, 80 and 90% for voricon-
azole, posaconazole and itraconazole, respectively. The
variability of the extraction eﬃciencies, between ana-
lytes, must be attributed to diﬀerences in their hydro-
phobicities and is a consequence of designing combined
methods for structurally very diverse drugs (Table 1).
However, even the lowest extraction eﬃciency of 50%
did not pose a problem due to the matched extraction
eﬃciency of the internal standards and the high analyte
concentrations (mg/L) being well within the sensitivity
of the instrument. The utility of the internal standards
and their ability to correct for extraction ineﬃciencies is
exempliﬁed in the recovery data. These experiments
involved the spiking of samples pre-extraction and
comparing the experimentally determined analyte
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Figure 2. (a) voriconazole, (b) posaconazole, (c) itraconazole. Red Trace – Multiple reaction monitoring trace from the post-column
infusion of each analyte (1mg/L) and elution of blank serum. Green Trace – Overlay showing usual analyte retention time.
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concentration to the known concentration of the spike.
As the experimental concentration is determined from
the response, and is therefore normalized to the internal
standard, any ineﬃciencies in the extraction process are
accounted for. The percentage recoveries are excellent
at 103, 95 and 103% for voriconazole, posaconazole
and itraconazole, respectively.
The hydrophobic nature of itraconazole also caused
problems during the development of the chromatog-
raphy. Initially, itraconazole did not fully elute from
the column and sample carryover was seen. The inclu-
sion of the rather extensive 3.5min, 98% mobile phase
B wash was initially trialled to remove the residual itra-
conazole before the injection of the next sample.
However, even with this wash step in place itracon-
azole, carryover was still seen and could not be
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Figure 3. Correlation between experimentally determined analyte concentrations and National External Quality Assurance
Scheme (NEQAS) targets (a) voriconazole, (b) posaconazole and (c) itraconazole. Bland–Altman plots showing absolute difference
(experimental – NEQAS ALTM) vs. average concentration for (d) voriconazole, (e) posaconazole and (f) itraconazole.
Table 3. Intra- and inter-assay precision.
Compound
Intra-assay precision
(n¼ 5)
Inter-assay precision
(n¼ 5)
Mean
(mg/L) CV (%)
Mean
(mg/L) CV (%)
Voriconazole 0.95 2.2 0.94 4.6
3.64 1.4 3.58 6.3
7.21 0.4 7.09 3.6
Posaconazole 0.33 2.8 0.33 8.9
2.67 4.7 2.69 8.2
Itraconazole 0.12 2.7 0.12 10.9
2.51 1.9 2.52 7.1
4.14 2.9 4.15 7.6
8 Annals of Clinical Biochemistry 0(0)
eradicated by further elongation of this wash step. We
therefore conclude there must be another source of the
carryover. In the literature Wong et al. noted that the
injector port required rinsing multiple times to help
overcome itraconazole carryover.16 In the light of this
information, the strength of wash, which the auto-
sampler used, was increased from 10% methanol to
100% methanol. The number of injector washes per-
formed between samples was also increased from one
to three. The combination of these changes eradicated
any sample carryover as evidenced by the area of the
blanks following injection of high concentrations of
each analyte being <5% of the LLMI area. The litera-
ture also reports the formation of posaconazole glucur-
onides in vivo which do not possess the same antifungal
eﬃcacy but can lead to over-quantiﬁcation in mass
spectrometry based methods due to in-source fragmen-
tation.17 These metabolites can, however, be easily
separated chromatographically, as is the case in this
assay and is evidenced by the lack of a positive bias
upon comparison to other methods.
The analytical range that should be covered for each
analyte was ﬁrst determined theoretically and then the
analytical performance was evaluated to make sure the
minimum performance criteria were met. Following a
review of the therapeutic ranges used by the antimicro-
bial reference laboratory along with the guidelines for
TDM of antifungal agents published by the British
Society for Medical Mycology and other literature,
the following analytical ranges were determined.12,18,19
Voriconazole 0.1–10mg/L, posaconazole 0.1–5.0mg/L
and itraconazole 0.1–5.0mg/L.
The minimum signal-to-noise ratio for any of the
quantiﬁer or qualiﬁer ions at the LLMI of 0.1mg/L
was 14:1, well above the minimum cut-oﬀ of 5:1. The
percentage variation at the LLMI was also well within
the minimum 20% standard suggesting the LLMI
could have been considerably lower than 0.1mg/L.
However, there is no clinical need to quantify concen-
trations <0.1mg/L and therefore this was not
attempted. Dilutions of certiﬁed reference material
showed the assay is linear to at least 10mg/L for vori-
conazole and 5mg/L for both posaconazole and
itraconazole. The correlation between the spiked con-
centration and the experimental concentration was
excellent and showed no signs of plateauing at the
higher end and therefore the analytical range could
also have been higher. Again, clinically the decision
was taken that concentrations higher than 10mg/L
and 5mg/L could be reported as greater than or re-
run on dilution and therefore there was no need to
extend the linear range. Development work has
shown that all three analytes dilute in the expected
linear manner. Both Chromsystems and Recipe provide
commercial calibrators and QCs for azole-based
antifungals, but neither company covers as broad an
analytical range as is shown here thus further highlight-
ing the utility of this new assay.
The intra- and inter-assay precision results were both
good and raised no concerns. The precision of this assay
was attributed to a combination of the simple yet robust
sample preparation procedure, the use of deuterated
internal standards and the well-resolved chromatog-
raphy. Both the direct correlation between the NEQAS
targets/experimental values and the Bland–Altman plots
highlights the accuracy of this method. The inter- and
intra-assay precision and percentage bias also compare
very favourably to other publish methods.20–22
In conclusion, this assay is a simple, robust and accur-
ate way to quantify three commonly used antifungals in
serum. The challenges that have arisen throughout the
development of this assay have not pushed the frontiers
of scientiﬁc practice but instead have centred around the
struggle to harness simple chemistries and pre-existing
infrastructure to develop a clinically necessary service.
The relatively low, but increasing, demand for this
assay necessitated the column and mobile phase to be
the same as the pre-existing assays run on the same
instrument therefore allowing this assay to be integrated
within the current workload and repertoire. It is hoped
that the ubiquitous choice of sample preparation
method, column and mobile phases will also allow
others clinical laboratories to add this assay to their
testing repertoire and in doing so improve patient care
nationally. Locally, the implementation of this method
will decrease sample turnaround times and consequently
give azole antifungal TDM much greater clinical utility
and result in optimal, tailored dosing for patients.
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